2021
Association Between Impaired Myocardial Flow Reserve on 82Rubidium Positron Emission Tomography Imaging and Adverse Events in Patients With Autoimmune Rheumatic Disease
Feher A, Boutagy NE, Oikonomou EK, Liu YH, Miller EJ, Sinusas AJ, Hinchcliff M. Association Between Impaired Myocardial Flow Reserve on 82Rubidium Positron Emission Tomography Imaging and Adverse Events in Patients With Autoimmune Rheumatic Disease. Circulation Cardiovascular Imaging 2021, 14: e012208. PMID: 34503339, PMCID: PMC8475774, DOI: 10.1161/circimaging.120.012208.Peer-Reviewed Original ResearchConceptsAutoimmune rheumatic diseasesMyocardial flow reserveLower myocardial flow reserveCox regression analysisAdverse eventsARDS diagnosisIndependent predictorsRheumatic diseasesPerfusion defectsFlow reserveNormal myocardial flow reserveLeft ventricular ejection fractionEnd pointGlobal myocardial flow reserveImpaired Myocardial Flow ReserveComorbidity-matched patientsSevere coronary calcificationCombined end pointCoronary microvascular dysfunctionHeart failure admissionsComposite end pointEvent-free survivalFramingham risk scoreLarge perfusion defectsRetrospective cohort analysis
2018
Rationale and design of the REgistry of Fast Myocardial Perfusion Imaging with NExt generation SPECT (REFINE SPECT)
Slomka PJ, Betancur J, Liang JX, Otaki Y, Hu LH, Sharir T, Dorbala S, Di Carli M, Fish MB, Ruddy TD, Bateman TM, Einstein AJ, Kaufmann PA, Miller EJ, Sinusas AJ, Azadani PN, Gransar H, Tamarappoo BK, Dey D, Berman DS, Germano G. Rationale and design of the REgistry of Fast Myocardial Perfusion Imaging with NExt generation SPECT (REFINE SPECT). Journal Of Nuclear Cardiology 2018, 27: 1010-1021. PMID: 29923104, PMCID: PMC6301135, DOI: 10.1007/s12350-018-1326-4.Peer-Reviewed Original ResearchMeSH KeywordsAgedArtificial IntelligenceAutomationCoronary AngiographyCoronary Artery DiseaseData CollectionDatabases, FactualFemaleFollow-Up StudiesHumansImage Processing, Computer-AssistedMachine LearningMaleMiddle AgedMyocardial Perfusion ImagingPrognosisRegistriesReproducibility of ResultsSoftwareTomography, Emission-Computed, Single-PhotonConceptsMyocardial perfusion imagingPharmacologic stressMajor adverse cardiac eventsAdverse cardiac eventsRevascularization resultsMulticenter registryCardiac eventsClinical variablesPrognostic outcomesResultsTo dateClinical dataPrognostic dataDiagnostic cohortSPECT-MPIImaging variablesMyocardial perfusionPrognostic cohortPerfusion imagingPatientsRegistryArtificial intelligence toolsNew artificial intelligence toolsQuantitative softwareCohortClinical image databaseTime Course of Common Clinical Manifestations in Patients with Transthyretin Cardiac Amyloidosis: Delay From Symptom Onset to Diagnosis
Papoutsidakis N, Miller EJ, Rodonski A, Jacoby D. Time Course of Common Clinical Manifestations in Patients with Transthyretin Cardiac Amyloidosis: Delay From Symptom Onset to Diagnosis. Journal Of Cardiac Failure 2018, 24: 131-133. PMID: 29305186, DOI: 10.1016/j.cardfail.2017.12.005.Peer-Reviewed Original Research
2016
Longitudinal systolic strain, cardiac function improvement, and survival following treatment of light-chain (AL) cardiac amyloidosis
Salinaro F, Meier-Ewert HK, Miller EJ, Pandey S, Sanchorawala V, Berk JL, Seldin DC, Ruberg FL. Longitudinal systolic strain, cardiac function improvement, and survival following treatment of light-chain (AL) cardiac amyloidosis. European Heart Journal - Cardiovascular Imaging 2016, 18: 1057-1064. PMID: 27965280, DOI: 10.1093/ehjci/jew298.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic Combined Chemotherapy ProtocolsBiomarkersBortezomibBostonCardiomyopathiesCohort StudiesEchocardiography, Doppler, ColorFemaleFollow-Up StudiesHeart Function TestsHospitals, UniversityHumansImmunoglobulin Light-chain AmyloidosisKaplan-Meier EstimateMaleMelphalanMiddle AgedPrognosisRetrospective StudiesROC CurveSensitivity and SpecificitySurvival AnalysisTreatment OutcomeVentricular Dysfunction, LeftConceptsB-type natriuretic peptideFree light chainsLight-chain cardiac amyloidosisCardiac amyloidosisCardiac biomarkersCR groupGlobal LSHigh-dose melphalanLongitudinal systolic strainSerum free light chainsCardiac functional impairmentCardiac functional improvementStandard echocardiographic measuresCardiac function improvementShort-term improvementBNP reductionComplete responseDiastolic functionEchocardiographic measuresHematologic responseNatriuretic peptideSystolic strainFunctional improvementFunction improvementFunctional impairment
2014
Preclinical Left Ventricular Diastolic Dysfunction in Metabolic Syndrome
Ayalon N, Gopal DM, Mooney DM, Simonetti JS, Grossman JR, Dwivedi A, Donohue C, Perez AJ, Downing J, Gokce N, Miller EJ, Liang CS, Apovian CM, Colucci WS, Ho JE. Preclinical Left Ventricular Diastolic Dysfunction in Metabolic Syndrome. The American Journal Of Cardiology 2014, 114: 838-842. PMID: 25084691, PMCID: PMC4162746, DOI: 10.1016/j.amjcard.2014.06.013.Peer-Reviewed Original ResearchConceptsHigher LA diameterLV diastolic dysfunctionVentricular diastolic dysfunctionDiastolic dysfunctionMetabolic syndromeLV massLA diameterLV hypertrophyYounger ageEarly risk factor modificationHigher left atrial diameterLeft ventricular diastolic dysfunctionAntihypertensive medication useLeft atrial diameterRisk factor modificationGender-adjusted analysesHigher LV massBody mass indexTissue Doppler imagingAtrial diameterDiastolic functionBlood pressureMedication useMass indexFactor modification